- Home
- MYX vs HURA Comparison
MYX vs HURA Comparison
Compare MYX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MYX | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 160.5M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYX | HURA |
|---|---|---|
| Price | $9.96 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 39.5K | ★ 279.2K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $0.41 |
| 52 Week High | $9.97 | $3.90 |
Technical Indicators
Market Signals| Indicator | MYX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 78.57 | 47.17 |
| Support Level | $9.89 | $2.11 |
| Resistance Level | N/A | $2.20 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 88.89 | 60.66 |
Price Performance
Historical ComparisonAbout MYX Maywood Acquisition Corp. 2 Class A Ordinary Share
Maywood Acquisition Corp 2 is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.